Safety of bilateral same-day intravitreal injections of anti-vascular endothelial growth factor agents

Miguel Ruão,1 María Andreu-Fenoll,2 Rosa Dolz-Marco,2 Roberto Gallego-Pinazo2 1Department of Ophthalmology, Centro Hospitalar Entre Douro e Vouga, Santa Maria da Feira, Portugal; 2Unit of Macula, Department of Ophthalmology, University and Polytechnic Hospital La Fe, Valencia,...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Ruão M, Andreu-Fenoll M, Dolz-Marco R, Gallego-Pinazo R
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2017
Materias:	bilateral intravitreal injections anti-VEGF endophthalmitis. Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/8c3ba54452044a43a4204c0d6dce4cc9
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:8c3ba54452044a43a4204c0d6dce4cc9
record_format	dspace
spelling	oai:doaj.org-article:8c3ba54452044a43a4204c0d6dce4cc92021-12-02T06:18:30ZSafety of bilateral same-day intravitreal injections of anti-vascular endothelial growth factor agents1177-5483https://doaj.org/article/8c3ba54452044a43a4204c0d6dce4cc92017-02-01T00:00:00Zhttps://www.dovepress.com/safety-of-bilateral-same-day-intravitreal-injections-of-anti-vascular--peer-reviewed-article-OPTHhttps://doaj.org/toc/1177-5483Miguel Ruão,1 María Andreu-Fenoll,2 Rosa Dolz-Marco,2 Roberto Gallego-Pinazo2 1Department of Ophthalmology, Centro Hospitalar Entre Douro e Vouga, Santa Maria da Feira, Portugal; 2Unit of Macula, Department of Ophthalmology, University and Polytechnic Hospital La Fe, Valencia, Spain Purpose: The aim was to evaluate the safety of bilateral same-day injections with intravitreal antiangiogenic drugs for macular diseases.Methods: Cross-sectional retrospective review of unilateral and bilateral same-day antiangiogenic injections was conducted between January 2011 and March 2016 in the Unit of Macula, University and Polytechnic Hospital La Fe (Valencia, Spain). A total of 8,172 injections were administered, among which 6,560 were unilateral and 1,612 were bilateral injections. Patients were included in the study regardless of the diagnosis. Ranibizumab and aflibercept were the antiangiogenic drugs used. The presence of endophthalmitis or retinal detachment was evaluated.Results: A total of 1 (0.012%) culture-proven endophthalmitis and 19 (0.233%) acute intraocular inflammations were registered. In the unilateral injections group, there were 18 (0.274%) acute intraocular inflammations and 1 (0.015%) culture-proven endophthalmitis. One (0.062%) of the 1,612 bilateral same-day injections had a unilateral acute intraocular inflammation, and there were no culture-proven endophthalmitis in this group.Conclusion: Bilateral same-day injections are more convenient for patients and their caregivers than the unilateral injections administered on different days. In our study, the prevalence of culture-proven endophthalmitis and acute intraocular inflammation was lower in the bilateral injections than in the unilateral group. These data support the idea that bilateral same-day injections are a safe and valid treatment to use in our clinical practice. Keywords: bilateral, intravitreal, injections, anti-VEGF, endophthalmitisRuão MAndreu-Fenoll MDolz-Marco RGallego-Pinazo RDove Medical Pressarticlebilateralintravitrealinjectionsanti-VEGFendophthalmitis.OphthalmologyRE1-994ENClinical Ophthalmology, Vol Volume 11, Pp 299-302 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	bilateral intravitreal injections anti-VEGF endophthalmitis. Ophthalmology RE1-994
spellingShingle	bilateral intravitreal injections anti-VEGF endophthalmitis. Ophthalmology RE1-994 Ruão M Andreu-Fenoll M Dolz-Marco R Gallego-Pinazo R Safety of bilateral same-day intravitreal injections of anti-vascular endothelial growth factor agents
description	Miguel Ruão,1 María Andreu-Fenoll,2 Rosa Dolz-Marco,2 Roberto Gallego-Pinazo2 1Department of Ophthalmology, Centro Hospitalar Entre Douro e Vouga, Santa Maria da Feira, Portugal; 2Unit of Macula, Department of Ophthalmology, University and Polytechnic Hospital La Fe, Valencia, Spain Purpose: The aim was to evaluate the safety of bilateral same-day injections with intravitreal antiangiogenic drugs for macular diseases.Methods: Cross-sectional retrospective review of unilateral and bilateral same-day antiangiogenic injections was conducted between January 2011 and March 2016 in the Unit of Macula, University and Polytechnic Hospital La Fe (Valencia, Spain). A total of 8,172 injections were administered, among which 6,560 were unilateral and 1,612 were bilateral injections. Patients were included in the study regardless of the diagnosis. Ranibizumab and aflibercept were the antiangiogenic drugs used. The presence of endophthalmitis or retinal detachment was evaluated.Results: A total of 1 (0.012%) culture-proven endophthalmitis and 19 (0.233%) acute intraocular inflammations were registered. In the unilateral injections group, there were 18 (0.274%) acute intraocular inflammations and 1 (0.015%) culture-proven endophthalmitis. One (0.062%) of the 1,612 bilateral same-day injections had a unilateral acute intraocular inflammation, and there were no culture-proven endophthalmitis in this group.Conclusion: Bilateral same-day injections are more convenient for patients and their caregivers than the unilateral injections administered on different days. In our study, the prevalence of culture-proven endophthalmitis and acute intraocular inflammation was lower in the bilateral injections than in the unilateral group. These data support the idea that bilateral same-day injections are a safe and valid treatment to use in our clinical practice. Keywords: bilateral, intravitreal, injections, anti-VEGF, endophthalmitis
format	article
author	Ruão M Andreu-Fenoll M Dolz-Marco R Gallego-Pinazo R
author_facet	Ruão M Andreu-Fenoll M Dolz-Marco R Gallego-Pinazo R
author_sort	Ruão M
title	Safety of bilateral same-day intravitreal injections of anti-vascular endothelial growth factor agents
title_short	Safety of bilateral same-day intravitreal injections of anti-vascular endothelial growth factor agents
title_full	Safety of bilateral same-day intravitreal injections of anti-vascular endothelial growth factor agents
title_fullStr	Safety of bilateral same-day intravitreal injections of anti-vascular endothelial growth factor agents
title_full_unstemmed	Safety of bilateral same-day intravitreal injections of anti-vascular endothelial growth factor agents
title_sort	safety of bilateral same-day intravitreal injections of anti-vascular endothelial growth factor agents
publisher	Dove Medical Press
publishDate	2017
url	https://doaj.org/article/8c3ba54452044a43a4204c0d6dce4cc9
work_keys_str_mv	AT ruaom safetyofbilateralsamedayintravitrealinjectionsofantivascularendothelialgrowthfactoragents AT andreufenollm safetyofbilateralsamedayintravitrealinjectionsofantivascularendothelialgrowthfactoragents AT dolzmarcor safetyofbilateralsamedayintravitrealinjectionsofantivascularendothelialgrowthfactoragents AT gallegopinazor safetyofbilateralsamedayintravitrealinjectionsofantivascularendothelialgrowthfactoragents
_version_	1718400001552416768

Safety of bilateral same-day intravitreal injections of anti-vascular endothelial growth factor agents

Ejemplares similares